RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact

Cancers

Apostolos Zaravinos¹  Benjamin Bonavida²  Stavroula Baritaki³  Ekaterini Chatzaki⁴ 

[1] Department of Life Sciences, School of Sciences, European University Cyprus, Nicosia 2404, Cyprus;Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA;Division of Surgical Oncology, School of Medicine, University of Crete, Heraklion, Crete 71500, Greece;Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis 68100, Greece;

关键词: RKIP;    cancer;    resistance;    metastasis;    EMT;    therapy;   

DOI  :  10.3390/cancers10090287

来源: DOAJ

【 摘 要 】

RAF-kinase inhibitor protein (RKIP) is a well-established tumor suppressor that is frequently downregulated in a plethora of solid and hematological malignancies. RKIP exerts antimetastatic and pro-apoptotic properties in cancer cells, via modulation of signaling pathways and gene products involved in tumor survival and spread. Here we review the contribution of RKIP in the regulation of early metastatic steps such as epithelial–mesenchymal transition (EMT), migration, and invasion, as well as in tumor sensitivity to conventional therapeutics and immuno-mediated cytotoxicity. We further provide updated justification for targeting RKIP as a strategy to overcome tumor chemo/immuno-resistance and suppress metastasis, through the use of agents able to modulate RKIP expression in cancer cells.

【 授权许可】

Unknown